 Completed successful IPO raising approximately 80.0 million in gross proceeds NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 Strengthened commercial capabilities with expanded management team and strategic collaboration with Veeva Systems 